cyc 202 has been researched along with Breast Cancer in 39 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (5.13) | 18.2507 |
| 2000's | 21 (53.85) | 29.6817 |
| 2010's | 14 (35.90) | 24.3611 |
| 2020's | 2 (5.13) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, ML; Dakshanamurthy, S; Deb, TB; Grindrod, SC; Paige, M; Yang, Y; Yenugonda, VM | 1 |
| de Dios, A; Lallena, MJ; Sánchez-Martínez, C; Sanfeliciano, SG | 1 |
| Li, J; Liang, C; Liu, C; Qiang, T; Ren, X; Shi, Z; Tian, L; Xing, Y | 1 |
| Alexiou, P; Fojtík, P; Growková, K; Hejret, V; Jorda, R; Kryštof, V; Palušová, V; Rotrekl, V; Štětková, M; Uldrijan, S; Valčíková, B; Verlande, A | 1 |
| Edwards, DP; Moore, NL; Weigel, NL | 1 |
| Akkoç, Y; Akyüz, KG; Arisan, ED; Çoker-Gürkan, A; Kerman, EM; Obakan, P; Palavan Ünsal, N | 1 |
| Appleyard, MV; Bray, SE; Kernohan, NM; Lane, DP; Levison, DA; Murray, KE; O'Neill, MA; Paulin, FE; Thompson, AM | 1 |
| Aubel, C; Bourhis, J; Connault, E; Deutsch, E; Haton, C; Maggiorella, L; Milliat, F; Opolon, P | 1 |
| Cappellini, A; Chiarini, F; Martelli, AM; McCubrey, JA; Ognibene, A | 1 |
| Komina, O; Maurer, M; Wesierska-Gadek, J | 1 |
| Borza, A; Komina, O; Maurer, M; Wesierska-Gadek, J | 1 |
| Akli, S; Biernacka, A; Bui, T; Hunt, KK; Keyomarsi, K; Moulder, S; Tucker, SL; Wingate, H | 1 |
| Cavino, M; D'Angelo, M; De Leon, G; Krucher, NA | 1 |
| Bareford, MD; Dent, P; Eulitt, P; Hossein, H; Martin, AP; Mitchell, C; Nephew, KP; Yacoub, A; Yang, C | 1 |
| Maurer, M; Wesierska-Gadek, J; Zulehner, N | 1 |
| Gritsch, D; Komina, O; Maurer, M; Węsierska-Gądek, J; Zulehner, N | 2 |
| Galons, H; Hunt, KK; Jabbour, NA; Joseph, B; Keyomarsi, K; Meijer, L; Multani, AS; Nanos-Webb, A; Oumata, N; Wingate, H | 1 |
| Nair, BC; Tekmal, RR; Vadlamudi, RK; Vallabhaneni, S | 1 |
| Arisan, ED; Coker, A; Obakan, P; Palavan-Unsal, N | 1 |
| Akli, S; Duong, MT; Hunt, KK; Keyomarsi, K; Liu, W; Lu, Y; Mills, GB; Wei, C; Wingate, HF; Yi, M | 1 |
| Bourhis, J; Chavaudra, N; Deutsch, E; Eschwege, F; Frascogna, V; Jeanson, L; Maggiorella, L; Milliat, F | 1 |
| Gueorguieva, M; Horky, M; Węsierska-Gądek, J; Wojciechowski, J | 1 |
| Barth, P; Göke, R; Lankat-Buttgereit, B; Samans, B; Schmidt, A | 1 |
| Cress, WD; Freeman, SN; Ma, Y | 1 |
| Gueorguieva, M; Horky, M; Wesierska-Gadek, J | 1 |
| Fischer, PM; Gianella-Borradori, A | 1 |
| Deans, AJ; Heierhorst, J; Khanna, KK; McArthur, GA; McNees, CJ; Mercurio, C | 1 |
| Fernando, R; Foster, JS; Henley, D; Isbill, M; Wimalasena, J | 1 |
| Goodyear, S; Sharma, MC | 1 |
| Ranftler, C; Schmitz, ML; Wesierska-Gadek, J | 1 |
| Gueorguieva, M; Herbacek, I; Ranftler, C; Wesierska-Gadek, J | 1 |
| Bloomston, M; Chou, FS; Dharker, N; Glickman, TS; Lee, D; McCaffrey, T; Mody, M; Pinzone, JJ; Pumfery, A; Ringel, MD; Wang, PS; Yang, Z | 1 |
| Kramer, MP; Maurer, M; Wesierska-Gadek, J | 1 |
| Gueorguieva, M; Kramer, MP; Lindner, H; Ranftler, C; Sarg, B; Wesierska-Gadek, J | 1 |
| De Maria, R; Eramo, A; López-Pérez, AI; López-Rivas, A; Ortiz-Ferrón, G; Yerbes, R | 1 |
| Mgbonyebi, OP; Russo, IH; Russo, J | 1 |
| David-Pfeuty, T | 1 |
| Horky, M; Kotala, V; Strnad, M; Trbusek, M; Uldrijan, S; Vojtesek, B | 1 |
3 review(s) available for cyc 202 and Breast Cancer
| Article | Year |
|---|---|
Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019).
Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Cell Cycle Checkpoints; Cyclin-Dependent Kinases; Drug Discovery; Humans; Indoles; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Pyrimidines; Transcription Factors | 2019 |
From Structure Modification to Drug Launch: A Systematic Review of the Ongoing Development of Cyclin-Dependent Kinase Inhibitors for Multiple Cancer Therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinases; Female; Humans; Pharmaceutical Preparations; Protein Kinase Inhibitors | 2022 |
Recent progress in the discovery and development of cyclin-dependent kinase inhibitors.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Clinical Trials as Topic; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Female; Flavonoids; Glomerulonephritis; Hematologic Neoplasms; HIV Infections; Humans; Molecular Sequence Data; Piperidines; Protein Kinase Inhibitors; Purines; Roscovitine; Transcription, Genetic | 2005 |
36 other study(ies) available for cyc 202 and Breast Cancer
| Article | Year |
|---|---|
Fluorescent cyclin-dependent kinase inhibitors block the proliferation of human breast cancer cells.
Topics: Adenine; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinases; Dansyl Compounds; Female; Fluorescent Dyes; Humans; Protein Kinase Inhibitors | 2011 |
CDK9 activity is critical for maintaining MDM4 overexpression in tumor cells.
Topics: Animals; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cyclin-Dependent Kinase 9; Drug Synergism; Humans; Imidazoles; MCF-7 Cells; Melanoma; Mice; Piperazines; Pluripotent Stem Cells; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Roscovitine; Sulfonamides; Transcription, Genetic; Transfection; Triazines | 2020 |
Cyclin A2 and its associated kinase activity are required for optimal induction of progesterone receptor target genes in breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Cyclin A2; Cyclin-Dependent Kinase 2; Female; Humans; Purines; Receptors, Progesterone; RNA, Messenger; Roscovitine | 2014 |
Polyamines modulate the roscovitine-induced cell death switch decision autophagy vs. apoptosis in MCF-7 and MDA-MB-231 breast cancer cells.
Topics: Apoptosis; Autophagy; Breast Neoplasms; Caspases; Cell Line, Tumor; Female; Humans; MCF-7 Cells; Mitochondria; Ornithine Decarboxylase; Phosphatidylinositol 3-Kinases; Polyamines; Protein Kinase Inhibitors; Purines; Roscovitine | 2015 |
Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Doxorubicin; Drug Synergism; Female; Humans; Mammary Neoplasms, Animal; Mice; Mice, Nude; Neoplasm Transplantation; Protein Kinase Inhibitors; Purines; Roscovitine | 2009 |
Cooperative effect of roscovitine and irradiation targets angiogenesis and induces vascular destabilization in human breast carcinoma.
Topics: Apoptosis; Base Sequence; Breast Neoplasms; Cell Line, Tumor; Culture Media, Conditioned; DNA Primers; Flow Cytometry; Humans; Immunohistochemistry; Neovascularization, Pathologic; Polymerase Chain Reaction; Purines; Radiation, Ionizing; Roscovitine; Vascular Endothelial Growth Factor A | 2009 |
The cyclin-dependent kinase inhibitor roscovitine and the nucleoside analog sangivamycin induce apoptosis in caspase-3 deficient breast cancer cells independent of caspase mediated P-glycoprotein cleavage: implications for therapy of drug resistant breast
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Caspase 3; Cell Line, Tumor; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Humans; Nucleosides; Purines; Pyrimidine Nucleosides; RNA, Messenger; Roscovitine | 2009 |
Roscovitine differentially affects asynchronously growing and synchronized human MCF-7 breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cell Division; Cell Proliferation; Cell Survival; Culture Media, Serum-Free; Cyclin-Dependent Kinases; DNA, Neoplasm; Dose-Response Relationship, Drug; Female; Flow Cytometry; G2 Phase; Humans; Hydroxyurea; Protein Kinase Inhibitors; Purines; Roscovitine; S Phase | 2009 |
Impact of roscovitine, a selective CDK inhibitor, on cancer cells: bi-functionality increases its therapeutic potential.
Topics: Apoptosis; Breast Neoplasms; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinases; Female; Flow Cytometry; G2 Phase; HeLa Cells; Humans; Immunoblotting; Phosphorylation; Protein Kinase Inhibitors; Purines; Roscovitine; Tumor Suppressor Protein p53; Uterine Cervical Neoplasms | 2009 |
Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors.
Topics: Aromatase Inhibitors; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cyclin E; Drug Resistance, Neoplasm; Female; G1 Phase; Humans; Letrozole; Molecular Weight; Nitriles; Postmenopause; Prognosis; Purines; Roscovitine; Triazoles | 2010 |
PNUTS knockdown potentiates the apoptotic effect of Roscovitine in breast and colon cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; DNA-Binding Proteins; E2F1 Transcription Factor; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Transgenic; Nuclear Proteins; Purines; RNA Interference; RNA-Binding Proteins; Roscovitine | 2010 |
Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Blotting, Western; Breast Neoplasms; Cell Death; Cell Line, Tumor; Cyclin-Dependent Kinases; Drug Synergism; Electrophoresis, Polyacrylamide Gel; ErbB Receptors; Female; Flavonoids; Fluorescent Antibody Technique; Gene Knockout Techniques; Humans; Indoles; Lapatinib; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Molecular Targeted Therapy; Myeloid Cell Leukemia Sequence 1 Protein; Piperidines; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrroles; Quinazolines; Roscovitine | 2010 |
Effect of anti-estrogen combined with roscovitine, a selective CDK inhibitor, on human breast cancer cells differing in expression of ER.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinases; Estrogen Receptor alpha; Female; Flow Cytometry; G1 Phase; G2 Phase; Humans; Immunoblotting; Purines; Roscovitine; Tamoxifen; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2011 |
Interference with ER-α enhances the therapeutic efficacy of the selective CDK inhibitor roscovitine towards ER-positive breast cancer cells.
Topics: Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Drug Synergism; Estrogen Receptor alpha; Flow Cytometry; G2 Phase; HeLa Cells; Humans; Immunoblotting; Membrane Potential, Mitochondrial; Phosphorylation; Protein Kinase Inhibitors; Purines; Roscovitine; Selective Estrogen Receptor Modulators; Serine; Tamoxifen; Time Factors | 2011 |
Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-α in human ER-positive breast cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Cycle; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinases; Dichlororibofuranosylbenzimidazole; Drug Synergism; Enzyme Inhibitors; Estradiol; Estrogen Receptor alpha; Estrogens; Female; Humans; Neoplasms, Hormone-Dependent; Phosphorylation; Purines; RNA Polymerase II; Roscovitine; Tamoxifen; Tumor Suppressor Protein p53 | 2011 |
Targeting low molecular weight cyclin E (LMW-E) in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromosome Aberrations; Cyclin E; Cyclin-Dependent Kinase 2; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Enzyme Induction; Female; Genomic Instability; Humans; Molecular Weight; Polyploidy; Protein Kinase Inhibitors; Purines; Roscovitine; Time Factors; Transfection | 2012 |
Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Co-Repressor Proteins; Cyclin D1; Cyclin-Dependent Kinase 2; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Humans; Mice; Mice, Nude; Nuclear Receptor Coactivator 3; Protein Kinase Inhibitors; Purines; Roscovitine; Transcription Factors; Xenograft Model Antitumor Assays | 2011 |
Inhibition of ornithine decarboxylase alters the roscovitine-induced mitochondrial-mediated apoptosis in MCF-7 breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Caspase 9; Cell Cycle Checkpoints; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Humans; Mitochondria; Ornithine Decarboxylase; Ornithine Decarboxylase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Purines; Roscovitine | 2012 |
LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients.
Topics: Acinar Cells; Animals; Benzenesulfonates; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Cyclin E; Cyclin-Dependent Kinase 2; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Mammary Glands, Animal; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Prognosis; Protein Isoforms; Proto-Oncogene Proteins B-raf; Purines; Pyridines; Retrospective Studies; Roscovitine; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases | 2012 |
Enhancement of radiation response by roscovitine in human breast carcinoma in vitro and in vivo.
Topics: Animals; Antigens, Nuclear; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Combined Modality Therapy; DNA Helicases; DNA Repair; DNA-Activated Protein Kinase; DNA-Binding Proteins; DNA, Neoplasm; Female; Humans; Ku Autoantigen; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Nuclear Proteins; Protein Serine-Threonine Kinases; Purines; Radiation-Sensitizing Agents; Roscovitine; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2003 |
Rapid onset of nucleolar disintegration preceding cell cycle arrest in roscovitine-induced apoptosis of human MCF-7 breast cancer cells.
Topics: Acetylation; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Caspases; Cell Cycle; Cell Fractionation; Cell Nucleolus; Cell Size; Cyclin-Dependent Kinases; Enzyme Activation; Histones; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Neoplasm Proteins; Nucleolin; Nucleolus Organizer Region; Phosphoproteins; Phosphorylation; Poly(ADP-ribose) Polymerases; Purines; RNA-Binding Proteins; Roscovitine; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2003 |
Programmed cell death protein 4 suppresses CDK1/cdc2 via induction of p21(Waf1/Cip1).
Topics: Apoptosis; Apoptosis Regulatory Proteins; Breast Neoplasms; Carcinoid Tumor; CDC2 Protein Kinase; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Colonic Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Endocrine Gland Neoplasms; Female; Humans; Insulinoma; Lung Neoplasms; Male; Pancreatic Neoplasms; Phosphorylation; Prostatic Neoplasms; Protein Kinase Inhibitors; Purines; Retinoblastoma Protein; RNA-Binding Proteins; Roscovitine | 2004 |
E2F4 deficiency promotes drug-induced apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; DNA-Binding Proteins; E2F Transcription Factors; E2F1 Transcription Factor; E2F4 Transcription Factor; Fibroblasts; Flavonoids; Humans; Lung Neoplasms; Mice; Mice, Knockout; Oxazoles; Piperidines; Protein Kinase Inhibitors; Purines; RNA, Small Interfering; Roscovitine; Thiazoles; Transcription Factors; Tumor Cells, Cultured | 2004 |
Roscovitine-induced up-regulation of p53AIP1 protein precedes the onset of apoptosis in human MCF-7 breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Breast Neoplasms; Caspase 3; Caspases; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; Membrane Potentials; Mitochondria; Phosphorylation; Phosphoserine; Proteins; Purines; Roscovitine | 2005 |
Cyclin-dependent kinase 2 functions in normal DNA repair and is a therapeutic target in BRCA1-deficient cancers.
Topics: Animals; Antineoplastic Agents; BRCA1 Protein; Breast Neoplasms; Cell Line, Tumor; Cyclin-Dependent Kinase 2; Disease Progression; DNA Damage; DNA Repair; DNA, Neoplasm; Female; Fibroblasts; Humans; Mice; Mice, Knockout; Purines; RNA, Neoplasm; RNA, Small Interfering; Roscovitine | 2006 |
Paclitaxel induced apoptosis in breast cancer cells requires cell cycle transit but not Cdc2 activity.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-Associated Death Protein; Blotting, Western; Breast Neoplasms; CDC2 Protein Kinase; Cell Cycle; Cell Line, Tumor; Cell Nucleus; Cell Survival; DNA Fragmentation; Estradiol; Flow Cytometry; Fulvestrant; Humans; Hydroxyurea; Inhibitor of Apoptosis Proteins; JNK Mitogen-Activated Protein Kinases; Microtubule-Associated Proteins; Microtubules; Neoplasm Proteins; Paclitaxel; Purines; RNA, Small Interfering; Roscovitine; Spindle Apparatus; Survivin; Thymidine; Transfection | 2007 |
Roscovitine regulates invasive breast cancer cell (MDA-MB231) proliferation and survival through cell cycle regulatory protein cdk5.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase 5; Dose-Response Relationship, Drug; Female; Humans; Nerve Tissue Proteins; Purines; Roscovitine | 2007 |
Roscovitine-activated HIP2 kinase induces phosphorylation of wt p53 at Ser-46 in human MCF-7 breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinases; Enzyme Activation; Humans; Immunoblotting; Phosphorylation; Protein Kinases; Protein Serine-Threonine Kinases; Purines; Roscovitine; Serine; Tumor Suppressor Protein p53 | 2007 |
Effect of distinct anticancer drugs on the phosphorylation of p53 protein at serine 46 in human MCF-7 breast cancer cells.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Doxorubicin; Female; Humans; Phosphorylation; Purines; Roscovitine; Serine; Tumor Suppressor Protein p53 | 2007 |
Rosiglitazone sensitizes MDA-MB-231 breast cancer cells to anti-tumour effects of tumour necrosis factor-alpha, CH11 and CYC202.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Chalcones; DNA Replication; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression; Humans; PPAR gamma; Purines; Response Elements; Reverse Transcriptase Polymerase Chain Reaction; Roscovitine; Rosiglitazone; Thiazolidinediones; Transcriptional Activation; Tumor Necrosis Factor-alpha | 2007 |
Resveratrol modulates roscovitine-mediated cell cycle arrest of human MCF-7 breast cancer cells.
Topics: Antineoplastic Agents; Antioxidants; Breast Neoplasms; Cell Count; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA; Female; Flow Cytometry; Humans; Purines; Resveratrol; Roscovitine; Stilbenes | 2008 |
A new, unexpected action of olomoucine, a CDK inhibitor, on normal human cells: up-regulation of CLIMP-63, a cytoskeleton-linking membrane protein.
Topics: Animals; Breast Neoplasms; Cell Line, Transformed; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinases; DNA; Dose-Response Relationship, Drug; Embryo, Mammalian; Enzyme Inhibitors; HL-60 Cells; Humans; Kinetin; Lung; Membrane Proteins; Mice; Purines; Roscovitine; Skin; Time Factors; Up-Regulation | 2007 |
Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspases; Cell Line, Tumor; Cell Membrane; Death Domain Receptor Signaling Adaptor Proteins; Down-Regulation; Drug Screening Assays, Antitumor; E2F1 Transcription Factor; Enzyme Activation; Fas-Associated Death Domain Protein; Female; Gene Expression Regulation, Neoplastic; Humans; Membrane Microdomains; Myeloid Cell Leukemia Sequence 1 Protein; Protein Isoforms; Proto-Oncogene Proteins c-bcl-2; Purines; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA, Messenger; RNA, Small Interfering; Roscovitine; TNF-Related Apoptosis-Inducing Ligand | 2008 |
Roscovitine induces cell death and morphological changes indicative of apoptosis in MDA-MB-231 breast cancer cells.
Topics: Actin Cytoskeleton; Actins; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Size; Cell Survival; Chromatin; Cyclin-Dependent Kinases; DNA, Neoplasm; Humans; Purines; Receptors, Estrogen; Roscovitine; Tumor Cells, Cultured | 1999 |
Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells.
Topics: Blotting, Western; Breast Neoplasms; Carcinoma; CDC2-CDC28 Kinases; Cell Cycle; Cell Death; Cell Line; Cell Line, Transformed; Cell Nucleolus; Cell Nucleus; Cell Transformation, Neoplastic; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinases; DNA Fragmentation; Dose-Response Relationship, Drug; Enzyme Inhibitors; G1 Phase; Humans; Inhibitory Concentration 50; Kinetin; Mitomycin; Nucleic Acid Synthesis Inhibitors; Nucleolin; Phosphoproteins; Protein Serine-Threonine Kinases; Purines; RNA-Binding Proteins; Roscovitine; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1999 |
Potent induction of wild-type p53-dependent transcription in tumour cells by a synthetic inhibitor of cyclin-dependent kinases.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Cyclins; Enzyme Inhibitors; Female; Fibroblasts; Gene Expression Regulation, Neoplastic; Humans; Kinetics; Melanoma; Mice; Osteosarcoma; Purines; Recombinant Proteins; Roscovitine; Transcription, Genetic; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2001 |